SRRA - Sierra Oncology, Inc.
1.4000 +0.02 (1.45%)
After hours: 6:09PM EDT
| Previous Close | 1.4100 |
| Open | 1.4000 |
| Bid | 1.3600 x 800 |
| Ask | 1.4200 x 800 |
| Day's Range | 1.3100 - 1.4100 |
| 52 Week Range | 1.0480 - 3.7000 |
| Volume | 696,255 |
| Avg. Volume | 362,301 |
| Market Cap | 103.07M |
| Beta (3Y Monthly) | 1.57 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7370 |
| Earnings Date | Aug 7, 2019 - Aug 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.67 |
- PR Newswire•8 days ago
Sierra to Present SRA737 Preliminary Clinical Data and Potential Next Steps at ASCO
- SRA737 Phase 1/2 Monotherapy and SRA737+LDG (Low Dose Gemcitabine) trials selected for poster presentations on June 1 st - - Sierra to hold Analyst & Investor Event at 6:00 am CT on June 3 rd featuring ...
- Associated Press•16 days ago
Sierra Oncology, Inc: 1Q Earnings Snapshot
The Vancouver, British Columbia-based company said it had a loss of 17 cents per share. The company's shares closed at $1.49. A year ago, they were trading at $1.99. _____ This story was generated by Automated ...
- CNW Group•16 days ago
Sierra Oncology Reports First Quarter 2019 Results
Sierra Oncology Reports First Quarter 2019 Results
- CNW Group•18 days ago
Sierra Oncology to Attend Two Investor Conferences in May
VANCOUVER , May 6, 2019 /CNW/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, today announced that members of its senior management team will be attending the SunTrust Robinson Humphrey 5th Annual Life Sciences Conference in New York on May 8th , and the Oppenheimer Oncology Insight Summit in New York on May 16th . Sierra Oncology is a clinical stage drug development company advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology.
- Simply Wall St.•27 days ago
Imagine Owning Sierra Oncology (NASDAQ:SRRA) And Trying To Stomach The 72% Share Price Drop
Sierra Oncology, Inc. (NASDAQ:SRRA) shareholders should be happy to see the share price up 18% in the last quarter. But that is meagre solace in the face of the shocking decline over three years. To wit, the share price sk...
- CNW Group•2 months ago
Sierra Reports Late-Breaking SRA141 Preclinical Data in Poster at AACR 2019
VANCOUVER , April 3, 2019 /CNW/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with unmet needs in hematology and oncology, reported preclinical data for its novel oral Cdc7 inhibitor, SRA141, in a late-breaking poster being presented today at the American Association of Cancer Research (AACR) Annual Meeting 2019 in Atlanta, Georgia . "Prior studies demonstrated that SRA141 potently and selectively inhibits Cdc7, resulting in robust anti-tumor efficacy in colorectal xenograft models, however, the compound's exact mechanism of action has not been characterized previously.
- PR Newswire•2 months ago
Sierra Reports Late-Breaking Preclinical Data for SRA737 Presented at AACR 2019
- Late-breaking oral presentation reports profound, durable synergistic activity for immunotherapy combined with SRA737+LDG, its Chk1 inhibitor plus low dose gemcitabine (LDG), in small cell lung cancer ...
- CNW Group•3 months ago
Sierra Oncology to Present at the Cowen 39th Annual Health Care Conference in Boston
VANCOUVER , March 5, 2019 /CNW/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, today announced that Dr. Christian Hassig , Chief Scientific Officer, will present an overview of the company at the Cowen 39th Annual Health Care Conference, scheduled for 10:00 a.m. ET on Wednesday , March 13. A live audio webcast and archive of the presentation will be accessible through the Sierra Oncology website at www.sierraoncology.com. Sierra Oncology is a clinical stage drug development company advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology.
- CNW Group•3 months ago
Sierra Oncology Reports 2018 Year End Results
Sierra Oncology Reports 2018 Year End Results
- CNW Group•3 months ago
Sierra Oncology Announces Late-Breaking Oral and Poster Presentations at AACR 2019 for SRA737 and SRA141 Preclinical Data
Sierra Oncology Announces Late-Breaking Oral and Poster Presentations at AACR 2019 for SRA737 and SRA141 Preclinical Data
- CNW Group•4 months ago
Sierra Oncology to Present at the DNA Damage Response Therapeutics Summit
VANCOUVER , Jan. 23, 2019 /CNW/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, today announced that its Chief Scientific Officer, Dr. Christian Hassig , will present "Addressing Intrinsic & Acquired PARP Inhibitor (PARPi) Resistance Through Chk1 Inhibition" at the DNA Damage Response (DDR) Therapeutics Summit in Boston, MA. "Targeting components of the DDR machinery that regulate replication stress, such as Chk1, represents an attractive therapeutic strategy to address both intrinsic and acquired PARPi resistance," noted Dr. Hassig.
- Simply Wall St.•4 months ago
Do Institutions Own Sierra Oncology, Inc. (NASDAQ:SRRA) Shares?
If you want to know who really controls Sierra Oncology, Inc. (NASDAQ:SRRA), then you'll have to look at the makeup of its share registry. Large companies usually have institutions as Read More...
- PR Newswire•6 months ago
Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib
- 44% of transfusion dependent myelofibrosis patients (multi-study aggregate N=152) were transfusion free for at least 12 weeks; 49% were transfusion free for at least 8 weeks - - Data from translational ...
- CNW Group•6 months ago
Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
- CNW Group•6 months ago
Sierra Oncology to Host Analyst Call Highlighting Clinical Data on Momelotinib's Anemia Benefit
VANCOUVER , Nov. 27, 2018 /CNW/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, today announced that it will host an Analyst & Investor call on Monday, December 3 rd at 4:30 pm Eastern Time (ET) to discuss newly reported clinical data for its lead drug candidate, momelotinib, a potent, selective and orally-bioavailable JAK1, JAK2 and ACVR1 inhibitor for the treatment of myelofibrosis. The call will be led by Dr. Nick Glover , President and CEO of Sierra Oncology and will include distinguished medical oncologist Dr. Srdan Verstovsek, MD, PhD, Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, Texas .
